Alpha Tau Medical rises on long-term data for its cancer therapy

Alpha Tau Medical

18/08/2023 13:12

** Shares of Israel based co Alpha Tau Medical Ltd  DRTS.O 
rise 14.17% to $4.11 premarket 
    ** Co announces initial long-term data for its cancer
therapy Alpha DaRT in patients with types of head and neck or
skin tumors
    ** Between February 2017 and December 2022, 81 lesions in 71
patients were treated with Alpha DaRT in four prospective
feasibility trials - co
     ** Adds 89% of treated lesions showed complete response to
the treatment while 10% had a partial response and one patient
was not evaluable
    ** These results bode well for the data readout from the
U.S. pivotal ReSTART trial- H.C. Wainwright
    ** Brokerage expects the study to complete enrollment in Q1
2024
    ** Up to last close, stock up ~13%

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))